Morphea, also known as localized scleroderma, is an inflammatory sclerosing skin disorder. There are multiple subtypes including plaque, linear, generalized, pansclerotic, and mixed. Pansclerotic morphea is extremely rare and has a severe, progressive phenotype characterized by circumferential involvement of the limbs and other body areas affecting the skin, subcutaneous tissue, muscle, and bone. It is often recalcitrant to treatment. We present a case of pansclerotic morphea responding rapidly to the anti–interleukin (IL)-6 receptor monoclonal antibody tocilizumab after progression during traditional immunosuppressive therapies.